


CLAIMS:

1. The use of a peptide of general Formula I



wherein


R_1 and R_2 , being equal or different, denote hydrogen, a saturated or unsaturated hydrocarbon moiety comprising from 1 to 10, in particular from 1 to 3, carbon atoms,

Z_1 denotes a histidine or proline moiety,

Z_2 denotes an arginine moiety, a peptide moiety or a protein moiety comprising an initial arginine moiety, in particular comprising from 2 to 30 amino acids,

which peptide has the biological property of matching the inducible VE-cadherin binding motif on the $\text{B}\beta$ -chain (i.e. $\text{B}\beta_{15-42}$) of human fibrin, for the preparation of a pharmaceutical preparation for the treatment of shock.

2. The use according to claim 1, characterized in that the peptide exhibits the general Formula II



wherein

Z_1 denotes a histidine or proline moiety,

Arg denotes an arginine moiety,

Z_3 denotes a proline or valine moiety,

Z_4 denotes a leucine or valine moiety,

Z_5 denotes a peptide moiety or a protein moiety in particular comprising from 2 to 30 amino acids or an alcohol moiety comprising from 1 to 10, in particular from 1 to 3, carbon atoms or an organic or inorganic base moiety.

3. The use according to claim 2, characterized in that Z_5 is a peptide moiety derived from the Aalpha-chain of the fibrin.

4. The use according to claim 2, characterized in that Z_5 is a peptide moiety derived from the Bbeta-chain of the fibrin.

5. The use according to claim 2, characterized in that

Z_5 is a peptide moiety comprising the amino acid sequence

Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Ile Ser Gly Gly Gly Tyr Arg

Z_1 is a histidine moiety,

Arg is an arginine moiety,

Z_3 is a proline moiety, and

Z_4 is a leucine moiety.

6. The use according to claim 2, characterized in that

Z_5 is a peptide moiety comprising the amino acid sequence

Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn
Tyr Lys

Z_1 is a proline moiety,

Arg is an arginine moiety,

Z_3 is a valine moiety, and

Z_4 is a valine moiety.

7. The use of a peptide which exhibits the N-terminal sequence

Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Tyr-Arg

which peptide has the biological property of matching the inducible VE-cadherin binding motif on the B β -chain (i.e. B β ₁₅₋₄₂) of human fibrin, for the preparation of a pharmaceutical preparation for the treatment of shock.

8. The use according to claim 7, characterized in that the peptide is

Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Tyr-Arg.

9. The use according to any of claims 1 to 8, wherein shock is associated with one or more from the group comprising bacterial toxins, disseminated intravascular coagulopathy, necrotizing fasciitis, haemorrhagic shock following viral infection, in particular caused by filovirus, arenaviridae, bunyaviridae, flavivirus, dengue, acute hemorrhagic respiratory failure caused by infectious agents or autoimmune diseases, organ failure after organ injury, in particular myocardial infarction, vascular surgery, clamping of organs, haemorrhagic shock, lung infarction, liver infarction, gut infarction, surgical procedures and stroke, and organ dysfunction of grafted organs.